Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP517563.RAZl_74LwNVMlrfQ4FKId2zoY_vtSZ-H-9cPMOx1qMcgQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP517563.RAZl_74LwNVMlrfQ4FKId2zoY_vtSZ-H-9cPMOx1qMcgQ130_assertion type Assertion NP517563.RAZl_74LwNVMlrfQ4FKId2zoY_vtSZ-H-9cPMOx1qMcgQ130_head.
- NP517563.RAZl_74LwNVMlrfQ4FKId2zoY_vtSZ-H-9cPMOx1qMcgQ130_assertion description "[Increased expression of integrin ?1, ?5, and/or ?2 was also observed in refractory tumor samples from patients with lung cancer treated with erlotinib and/or gefitinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP517563.RAZl_74LwNVMlrfQ4FKId2zoY_vtSZ-H-9cPMOx1qMcgQ130_provenance.
- NP517563.RAZl_74LwNVMlrfQ4FKId2zoY_vtSZ-H-9cPMOx1qMcgQ130_assertion evidence source_evidence_literature NP517563.RAZl_74LwNVMlrfQ4FKId2zoY_vtSZ-H-9cPMOx1qMcgQ130_provenance.
- NP517563.RAZl_74LwNVMlrfQ4FKId2zoY_vtSZ-H-9cPMOx1qMcgQ130_assertion SIO_000772 23872583 NP517563.RAZl_74LwNVMlrfQ4FKId2zoY_vtSZ-H-9cPMOx1qMcgQ130_provenance.
- NP517563.RAZl_74LwNVMlrfQ4FKId2zoY_vtSZ-H-9cPMOx1qMcgQ130_assertion wasDerivedFrom befree-20150227 NP517563.RAZl_74LwNVMlrfQ4FKId2zoY_vtSZ-H-9cPMOx1qMcgQ130_provenance.
- NP517563.RAZl_74LwNVMlrfQ4FKId2zoY_vtSZ-H-9cPMOx1qMcgQ130_assertion wasGeneratedBy ECO_0000203 NP517563.RAZl_74LwNVMlrfQ4FKId2zoY_vtSZ-H-9cPMOx1qMcgQ130_provenance.